Arrowtech brings you the
On/Go™ COVID-19
Antigen Self-Test

Learn More
slide

The On/Go™ COVID-19 Antigen Self-Test

The On/Go™ COVID-19 Antigen Self-Test is an over-the-counter, self-administered rapid test that delivers results in just 10 minutes, with 95% accuracy.* On/Go is proudly manufactured in the United States.

This test is authorized for non-prescription home use for individuals with symptoms of COVID-19 within the first 7 days of symptom onset. The On/Go Self-Test is also suitable for individuals without symptoms or other epidemiological reasons to suspect a COVID-19 infection when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
slide

On/Go is a solution like no other

An easy-to-use self-test paired with an intuitive mobile app to deliver accurate results in just 10 minutes.

Test Details

  • 95% accurate*
  • Rapid results at 10 minutes
  • Detects the antigen protein of all known major COVID-19 variants of concern (including Delta and Omicron)
  • Authorized for non-prescription self-use for individuals 14 years or older or adult-collected samples from individuals 2 years or older
  • For individuals with or without symptoms
  • Qualitative detection of SARS-CoV-2 nucleocapsid protein antigen via lower nasal swab samples
  • Only for use under the Emergency Use Authorization (EUA)
  • Single test for individuals with symptoms within 7 days of onset or two tests over two or three days for individuals without symptoms
  • For in vitro diagnostic use only
* PPA: 87%, NPA: 98% (see IFU for more details)
slide

Before You Test, Install the On/Go App

An easy to use iOS and Android mobile app delivers an intuitive testing experience. The On/Go app provides rapid test results, tracks your testing history and lets you easily share results with those who need to know.

Disclaimer

This product has not been FDA cleared or approved but has been authorized by FDA under an Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.